Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Panacea opens cancer drug production facility in India
The new manufacturing facility which is set up in compliance with regulatory standards is expected to increase the annual production capacity to around 1.2 million vials. Panacea Biotec
The new manufacturing facility which is set up in compliance with regulatory standards is expected to increase the annual production capacity to around 1.2 million vials. Panacea Biotec
The submission is based on trial in which significant reductions were observed in all atherogenic lipoproteins evaluated for patients receiving KYNAMRO who are already receiving a regimen of
Covis will market and distribute Zantac Injection in three SKUs, including 2mL, 6mL and 40ml vials, and expects to launch the product in 50mg premixed bags, shortly. The
The financial terms of the agreement have not been disclosed. AKESOgen and London Genetics will collaborate to provide pharmacogenetic solutions, such as novel biomarker and assay development services
The study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf and has randomized over 540 patients at approximately 90 sites around the world. The randomized,
The sale is expected to close on 30 June 2012 and the financial terms of the agreement have not been disclosed, the Canadian Business reported. Halo plans to
The new deal extends and expands the companies’ previous three-year agreement from 2009. BioSeek will expand the use of its BioMAP platform to evaluate Merck small molecule compounds
As per the agreement, the term of the development and marketing agreement has been extended from July 2016 to March 2021 and certain financial terms, such as co-promotion
The development and delivery of prototype formulations met the pre-specified attributes under its agreement to license Acuform technology and data to Boehringer Ingelheim. Depomed and Boehringer Ingelheim have
Optimer is eligible to receive a one-time, up-front cash payment of $20m and additional cash payments of up to $70m upon the achievement of certain regulatory and commercial